Teva slips

Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva slips as 2025 earnings outlook misses estimates
Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below consensus. Read more here.
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator instructions] And I hand it over to your host, Chris Stevo, SVP, investor relations. Please go ahead.
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,
Teva Pharmaceutical Shares Fall 13% Following Lower-than-Expected Q4 Results
Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading
Teva Pharmaceutical shares tumble as 2025 outlook disappoints
NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below expectations.
Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries ( TEVA -13.03%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug ...
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.
FiercePharma8h
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
American Association of Individual Investors2h
Why Teva Pharmaceutical Industries Limited’s (TEVA) Stock Is Down 13.89%
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...
Teva falls -12.5%
Teva (TEVA) is down -12.5%, or -$2.69 to $18.84.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...
globes.co.il11h
Teva falls sharply on disappointing 2025 guidance
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by ...